Search

Displaying results 2081 - 2090 of 7687 in total
  1. Drug

    Alanosine

    go.drugbank.com/drugs/DB05540
    Investigational

    An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.

  2. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    Adrafinil does not currently have FDA approval and is thus unregulated in the United States. … It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

  3. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965].

  4. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer

  5. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  6. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric

  7. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood.

  8. Drug

    Vinblastine

    go.drugbank.com/drugs/DB00570
    ApprovedInvestigational

    Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

  9. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    the data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  10. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]